SW033291
SW033291 (PGDHi) is a drug which acts as a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
SW033291 (PGDHi) is a drug which acts as a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The (R) or (+) enantiomer is more active, though much of the earlier research used the racemic mix.
It increases levels of prostaglandin E2 and promotes tissue regeneration, and has shown beneficial effects for numerous potential medical applications in animal studies, including recovery from bone marrow transplant, acute kidney injury, liver damage, diabetes, heart failure, cartilage regrowth, sarcopenia, and neurological conditions such as Alzheimer's disease and traumatic brain injury.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1335401336 under CC BY-SA 4.0; modifications have been made.